Since we're talking glucosamine, I'll repost one of the abstracts from the ECTRIMS et al conference a couple of weeks ago:
Effects of glucosamine sulfate on multiple sclerosis progression: a randomized, placebo-controlled trial
V. Shaygannejad1; F. Ashtari1; M. Janghorbani2
1. Isfahan Neuroscience Research Center ( INRC), Isfahan, Iran.
2. Isfahan University of Medical Sciences ( IUMS), Isfahan, Iran.
Glucosamine, a natural glucose derivative and an essential component of glycoproteins and proteoglycans, has been safely used to relieve osteoarthritis, but there is no evidence to support its use in multiple sclerosis (MS).
The aim of this study was to evaluate the effectiveness of glucosamine sulfate in the prevention of progression of MS.
One hundred and twenty definite MS patients age 17 to 55 years were randomly allocated to receive a 6-month treatment course of either oral glucosamine sulfate (1500 mg/day) or placebo. Response to treatment was assessed at 6 months after start of therapy.
The results of the study demonstrated that a slight but significant improvement in relapse rate occurred in the glucosamine sulfate group. Of the 60 patients treated with glucosamine sulfate, the mean (SD) of relapse rate decreased from 1.2 (0.7) at baseline to 0.5 (0.6) at the end of the study period (P<0.01). Correspondingly, in the 60 patients treated with placebo, the mean (SD) of relapse rate did not change. After 6 months, 53.3% of patients receiving glucosamine sulfate remained relapse-free compared with 48.3% of those given placebo. The average Expanded Disability Status Scale (EDSS) score at the end of trial did not changed between glucosamine sulfate and placebo group (mean difference, 0.2; 95% CI, -0.4, 0.8).
Thus, this study suggests that treatment with glucosamine sulfate significantly reduces relapse rate in patients with MS. No significant differences were seen between glucosamine sulfate and placebo on the mean (SD) EDSS.